Royalty Report: Medical, Device, Surgical – Collection: 6202


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 7


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7

Primary Industries

  • Medical
  • Device
  • Surgical
  • Supply
  • Catheter
  • cardiac
  • Technical Know How

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6202

License Grant
The Licensor, an individual, assigned the patents for his inventions to certain pediatric cardiology medical devices and techniques and know-how to the Licensee.
License Property
Our Amplatzer occlusion devices offer minimally invasive, transcatheter treatments that have been clinically shown to be highly effective in defect closure.

Our AMPLATZER occlusion devices utilize our expertise in braiding nitinol, a metal alloy with superelastic and shape-memory characteristics, and designing transcatheter delivery systems.

IPSCIO Record ID: 3938

License Grant
U.S. Corp. announced that a federal U.S. district court jury in San Francisco awarded it past damages and on-going royalties, finding that another U.S. corporation's manufacture, sale and use of its Amplatzer®Occluder and vascular plug product lines infringed claims of two U.S. patents owned by licensor.
License Property
The patents involved in this case are U.S. Patent No's. 6,306,141 and 5,067,957, known as the Jervis patents. The 141 patent covers self-expanding medical devices using stress to restrain a metal alloy that will expand to its original shape upon being released from a restraint, such as a sheath. For example, this invention allows doctors to locate and expand a medical device to repair holes in the heart, treat aortic aneurysms, place stents within the peripheral vasculature or treat damaged or diseased heart valves via a less invasive, transcatheter heart valve procedure. The 957 patent, which expired in 2004, covers a method of treatment using shape memory alloys, such as nitinol, in accordance with the Jervis inventions.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 6158

License Grant
The Licensee and the Licensors, two individuals, entered into a worldwide License agreement for  the Invention, including without limitation the entire right, title and interest to the Patent Rights to the  Atrial Septal Defect (ASD) and a Patent Ductus Arteriosus (PDA) Device Percutaneous Catheter Directed Intravascular Occlusion Devices – US Patent 5725552 .  The agreement shall continue in full force and effect for the commercial life of all products covered under this Agreement unless otherwise terminated. Inventors also grant the Licensee the exclusive right, but not the obligation, to use one or all of the inventors, names in its name or trademark for any Products and to use one or all of the inventors’ names in connection with the advertising and marketing of Products.  Intra-cardiac devices are used in various medical procedures
License Property
Atrial septal defect (ASD) is a form of congenital heart defect that enables blood flow between two compartments of the heart called the left and right atria.
Patent ductus arteriosus (PDA) is a congenital disorder in the heart wherein a neonate's ductus arteriosus fails to close after birth.

IPSCIO Record ID: 370271

License Grant
Licensor of Germany licensed patents to Licensee for a term of 20 years relating to technologies used in the JAWs staple system.
License Property
The JAWSTM Nitinol Staple System uses superelastic nitinol and a simple insertion method to gain rigid compression across an osteotomy site to fix small bone fragments together. Unlike many competitive implants, the JAWSTM Nitinol Staple System has a lightweight titanium inserter that allows the surgeon to fully seat the staple before it is released from the inserter.  

Of the nine patents licensed from Licensor, six are utility patents and three are design patents. All of the Licensor patents relate to technologies used in our JAWs staple system. Of the patents licensed from Licensor, six are U.S. patents, one is a E.U. patent, one is a Chinese patent and one is a Japanese patent. The patents licensed from Licensor begin to expire in 2033.

Field of Use
Field of use is for use in an osteotomy, arthrodesis and fragment fixation of bones and joints of the foot including fixation of small bone fragments.

The JAWSTM Nitinol Staple System uses superelastic nitinol and a simple insertion method to gain rigid compression across an osteotomy site. Unlike many competitive implants, the JAWSTM Nitinol Staple System has a lightweight titanium inserter that allows the surgeon to fully seat the staple before it is released from the inserter. This allows for final placement of the staple before the staple compresses the osteotomy site.

IPSCIO Record ID: 242249

License Grant
University hereby grants to each Canadian Licensee a worldwide non-exclusive, royalty-bearing right and license, with the right to sublicense, under the Penn Know-How to make, have made, use, distribute, sell, offer for sale, develop, promote, import, export and otherwise exploit Licensed Products in the Field of Use during the Term (the “License”).
License Property
Licensed Product means any Product relating to mitral valves and made, used or sold by utilizing or practicing Licensor Know-How,  including the “Tiara” transcatheter mitral valve product and any other next generation of “Tiara” product.  Tiaraâ„¢ is a minimally invasive transcatheter device for patients who experience severe mitral regurgitation utilizing the Licensor know-how.

“Licensed Product” means any Product (i) relating to mitral valves and (ii) made, used or sold by utilizing or practicing Penn Know-How.

Field of Use
The Licensee is a medical device company that specializes in developing, manufacturing, and marketing cardiovascular products including Tiara. Tiara is implanted in the heart using a minimally invasive, transapical transcatheter approach without the need for open-heart surgery or use of a cardiac bypass machine.

IPSCIO Record ID: 27092

License Grant
The Company hereby grants to Licensee and its Affiliates, upon the terms and subject to the conditions set forth herein, a worldwide, exclusive right and sublicense under USC Patent Rights in the Field of Use.
License Property
Guardian Embolization Protection System patented technology for primary use in the neurointerventional and cardiology markets these markets focus on arteries and veins leading to the brain and those in the heart, and the removal of blockages in these veins and arteries.  The device is designed to prevent deadly embolisms during surgery to clear blocked arteries and prevent strokes and heart attacks.  The key to this device, known as the Guardian System, is a thin string of wire, really a metal tube not much larger in diameter than a human hair, with a marble-sized balloon attached toward the end.
Field of Use
'Field of Use' shall mean diagnostic and/or therapeutic devices used in the treatment or management of patients via the carotid artery or other arteries or veins.

IPSCIO Record ID: 66891

License Grant
The Licensee entered into a Patent Assignment and Licensing Agreement with an undisclosed third party which was later amended in November 2012.
License Property
The patented technology is used in the AirSeal products. As part of the Licensing Agreement, proprietary patents and patent applications were sold, assigned and transferred to the Licensee so that the Licensee could develop and commercialize products in the AirSeal® System optimizing the laparoscopic environment and providing stability in the abdominal cavity during minimally invasive surgery.  AirSeal is a proprietary surgical access management system, which offers significant clinical benefits for patients and economic benefits for healthcare providers.
Field of Use
The Licensee is a commercial stage global medical technology company marketing a device used in Minimally Invasive Surgery.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.